Pharmacovigilance medical reviewer must resolve whether to drop a secondary

Situation

In a safety team sitting on a new disproportionate signal, pediatric investigation plan vs. disease epidemiology is the evidence after an AdCom briefing document that overstates subgroup findings. Pharmacovigilance medical reviewer has to pick Proceed under protocol or Pause the pathway for this Pharma & Life Sciences FDA Response and Labeling close using pediatric investigation plan vs. disease epidemiology.

Decision

Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using pediatric investigation plan vs. disease epidemiology after an AdCom briefing document that overstates subgroup findings — specific to pediatric investigation plan vs. disease epidemiology after an AdCom briefing document that overstates subgroup findings on this Pharma & Life Sciences FDA Response and Labeling file for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.

Hypotheses to test

• Pharmacovigilance medical reviewer can defend Proceed under protocol from pediatric investigation plan vs. disease epidemiology after an AdCom briefing document that overstates subgroup findings in a Pharma & Life Sciences challenge.
• Pharmacovigilance medical reviewer cannot defend Proceed under protocol from pediatric investigation plan vs. disease epidemiology; Pause the pathway is what the extract actually supports after an AdCom briefing document that overstates subgroup findings.
• An AdCom briefing document that overstates subgroup findings never reached the population in pediatric investigation plan vs. disease epidemiology — reopen intake, do not close to drop a secondary.
• Two facts in pediatric investigation plan vs. disease epidemiology after an AdCom briefing document that overstates subgroup findings conflict for pharmacovigilance medical reviewer; hold this FDA Response and Labeling file.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in pediatric investigation plan vs. disease epidemiology after an AdCom briefing document that overstates subgroup findings — specific to pediatric investigation plan vs. disease epidemiology after an AdCom briefing document that overstates subgroup findings on this Pharma & Life Sciences FDA Response and Labeling file for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.